DNA methylation mediates the genetic variants on ticagrelor major metabolite elimination and platelet function recovery after ticagrelor discontinuation

Epigenomics. 2022 May;14(10):601-613. doi: 10.2217/epi-2021-0461. Epub 2022 May 16.

Abstract

Aim: To investigate the influence of DNA methylation on ticagrelor major metabolite M8 elimination and platelet function recovery after ticagrelor discontinuation. Materials & methods: Among healthy Chinese subjects, a causal inference test was conducted to identify CpG sites located on absorption, distribution, metabolism and excretion genes that mediate genetic variants on M8 elimination. Colocalization analysis was used to identify the CpG sites that shared causal variants with platelet function recovery. Results: cg05300248 (CHST9), cg05640674 (SLC22A5) and cg00846580 (DHRS7) mediated genetic variants on the M8 elimination. cg06338150 (NOTCH1) and cg17456097 (RPS6KA1) were demonstrated to have strong evidence of colocalization with platelet function recovery. Conclusion: The results provide new biological insights into the impact of DNA methylation on M8 elimination and platelet function recovery after ticagrelor discontinuation. Clinical trial registration: clinicaltrials.gov, identifier: NCT03092076.

Keywords: DNA methylation; causal inference test; colocalization analysis; methylation quantitative trait loci; platelet function recovery; ticagrelor.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine
  • DNA Methylation*
  • Humans
  • Oxidoreductases
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists*
  • Recovery of Function
  • Solute Carrier Family 22 Member 5
  • Sulfotransferases
  • Ticagrelor / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • SLC22A5 protein, human
  • Solute Carrier Family 22 Member 5
  • DHRS7 protein, human
  • Oxidoreductases
  • CHST9 protein, human
  • Sulfotransferases
  • Ticagrelor
  • Adenosine

Associated data

  • ClinicalTrials.gov/NCT03092076